local_hospital

Centre Hospitalier Universitaire De Poitiers

Address
lock Available on a paid plan

Oncology and Solid Tumors

The Service d’oncologie médicale at Centre Hospitalier Universitaire De Poitiers is highly active in oncology, with a strong focus on a wide range of solid tumors and advanced cancers. Research here includes studies aimed at testing new treatment strategies, improving disease control, and comparing emerging therapies with current standards of care.

  • Breast, lung, gastrointestinal, and genitourinary cancers
  • Rare and difficult-to-treat tumors such as sarcomas, neuroendocrine cancers, and biliary tract cancers
  • Trials exploring better treatment effectiveness, recurrence prevention, and personalized cancer care

Much of the work centers on advanced or metastatic disease, reflecting the site’s broad role in evaluating innovative options for patients with limited treatment choices.

Hematology and Blood Disorders

Another major research area is hematology, covering both malignant and non-malignant blood disorders. The site contributes to studies in leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and amyloidosis, with the goal of improving survival, reducing symptoms, and refining long-term disease control.

  • Acute and chronic leukemias, including acute lymphoblastic leukemia and acute myeloid leukemia
  • Lymphomas, multiple myeloma, myelodysplastic syndromes, and myelofibrosis
  • Research on treatment effectiveness, transplant-related care, and better supportive approaches

This hematology portfolio shows a strong interest in both newly diagnosed and relapsed disease, including studies designed to improve outcomes in Centre Hospitalier Universitaire De Poitiers patients with complex hematologic conditions.

Cardiovascular and Metabolic Research

The site also supports substantial research in cardiovascular disease and related metabolic disorders. Trials address conditions such as myocardial infarction, heart failure, hypertension, atherosclerosis, thrombosis, and diabetes, often with the aim of preventing complications and improving long-term outcomes.

  • Acute coronary syndromes, stroke, and other vascular events
  • Heart failure, valvular disease, hypertension, and cardiomyopathy
  • Studies evaluating prevention strategies, treatment effectiveness, and risk reduction

Research in this area combines acute care and chronic disease management, highlighting the center’s interest in both immediate intervention and long-term cardiovascular protection.

Autoimmune, Inflammatory, and Rheumatologic Diseases

Clinical research at Centre Hospitalier Universitaire De Poitiers extends to immune-mediated diseases, including rheumatology, systemic autoimmune disorders, and inflammatory conditions. These studies aim to improve symptom control, reduce disease activity, and evaluate more targeted treatment options.

  • Systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, and juvenile idiopathic arthritis
  • Vasculitis, systemic sclerosis, myelitis, and other inflammatory syndromes
  • Trials focused on better disease control, safer treatment options, and improved quality of life

This research area reflects a strong commitment to chronic conditions where immune system regulation is central to care.

Respiratory, Infectious, and Critical Care Medicine

The site has an active portfolio in respiratory medicine, infectious diseases, and critical care. Research includes severe infections, pneumonia, influenza, chronic lung disease, pulmonary hypertension, and intensive care complications, with a strong emphasis on improving outcomes in hospitalized and critically ill patients.

  • COVID-19, sepsis, pneumonia, and bloodstream or postoperative infections
  • COPD, asthma, bronchiectasis, pulmonary hypertension, and interstitial lung disease
  • Studies testing new ways to treat infection, reduce complications, and support critically ill patients

These trials often address urgent clinical problems where timely treatment and better supportive care can make a major difference.

Neurology, Ophthalmology, and Other Specialized Fields

Beyond its major disease areas, the research environment at this hospital includes neurology, eye diseases, and several other specialized fields. Studies cover Parkinson’s disease, multiple sclerosis, stroke, macular degeneration, and rare neurological or pediatric conditions, often focusing on treatment effectiveness or better disease monitoring.

  • Parkinson’s disease, multiple sclerosis, stroke, and traumatic brain injury
  • Macular degeneration, diabetic macular edema, and retinoblastoma
  • Trials aimed at improving diagnosis, symptom control, and functional outcomes

Across these diverse areas, the site’s research reflects a broad clinical mission that combines innovation in medical oncology with important work in chronic disease management and supportive care.

Site Overview

assignment
633
connected trials
corporate_fare
210
sponsors
science
722
IMPs

Activity Indicator

Last 6 months

43
Trials started
-7% vs previous period.
46
Trials started 6–12 months ago
633
Total trials linked
Highly Active
trending_downDeclining-7%
6
10
11
6
9
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 32 therapeutic areas and 15 of 722 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 671 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
348
Sponsors (total)
210
Active sponsors
146

Sponsor Network

Top 146 by active trials.

lock +145 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +89 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
633
Outperforms 99% of sites
public
Therapeutic diversity
32areas
Outperforms 98% of sites
groups
Sponsor diversity
210sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier Universitaire De Poitiers

lock Showing 1 of 633 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studiesBayer Consumer Care AGPhase IIINot RecruitingOct 2020

IMP list

lock Showing 1 of 722 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Fluorouracil59Unknown2014-12-232026-07-20

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.